பாண்டியன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பாண்டியன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பாண்டியன் Today - Breaking & Trending Today
Selexis SA: Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody Pandion will leverage Selexis proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases Selexis SA, a JSR Life Sciences company, announced today that it has signed a service agreement with Pandion Therapeutics, Inc., to advance the development of Pandion s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Under the terms of the agreement, Pandion will utilize Selexis proprietary SURE technology Platform to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials. Pandion s selection of Selexis as a cell line development partner is a testament to the value of our SURE ....
By Reuters Staff 1 Min Read FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid (Reuters) - Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, to expand its portfolio of drugs that target autoimmune diseases. The $60-per-share deal represents about 134% premium to Pandion’s closing price on Wednesday. Pandion’s lead drug candidate, PT101, last month met its main goals of safety and tolerability in an early-stage trial in patients with autoimmune diseases. The transaction is expected to close in the first half of 2021, the companies said in a joint statement. ....
IPO Lockup Expiration Alert: Pandion Therapeutics (PAND) Pandion Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients suffering from autoimmune diseases. The company s lead product candidate is PT101, for which a phase 1a/2b clinical trial in ulcerative colitis is expected to start in mid-2021 and phase II clinical trial in systemic lupus erythematosus is expected to start in the second half 2021. Also in the pipeline are a couple of compounds in pre-clinical testing like PT627 for the treatment of autoimmune disease, and PT002 and PT001, for the treatment of gastrointestinal and liver diseases. Pandion Therapeutics made its debut on The Nasdaq Global Select Market on July 17, 2020, offering its shares at a price of $18 each and as mentioned above, the 180 day lockup period expires on January 13. ....
The Straits Times Dr R. Theyvendran was a member of the MDIS governing council from 1989 to 2020.PHOTO: MDIS https://str.sg/JR9u They can read the article in full after signing up for a free account. Share link: Or share via: Sign up or log in to read this article in full Sign up All done! This article is now fully available for you Read now Get unlimited access to all stories at $0.99/month for the first 3 months. Get unlimited access to all stories at $0.99/month for the first 3 months. including the ST News Tablet worth $398. Let s go! Spin the wheel for ST Read and Win now. ....
D.B.S.Jeyaraj More than eleven years have passed since the War between the Sri Lankan Armed Forces and Liberation Tigers of Tamil Eelam(LTTE) organization concluded. The lengthy conflict described at one time as South Asia’s longest war came to an end after the military defeat of the LTTE in May 2009. Many of the military triumphs achieved by both sides at different times during the course of the war are now being relegated to the realm of the forgotten.This column intends to focus this week on an incident that grabbed worldwide attention when it happened thirteen years ago. ....